TIDMINS

RNS Number : 5293V

Instem plc

15 January 2013

15 January 2013

Instem plc

("Instem", or the "Company")

Director/PDMR Shareholding

Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces that Chief Executive Officer, Phil Reason has been granted options over 23,429 ordinary shares of 10p each ("Ordinary Shares") and Chief Financial Officer, Nigel Goldsmith has been granted options over 15,000 Ordinary Shares. These options become exercisable after a period of three years subject to market based performance criteria, pursuant to the rules of the Company's All Staff LTIP and approved by the Remuneration Committee on 18 December 2012. The exercise price of 90p represents the closing mid-market price of the Ordinary Shares as at 14 January 2013.

For further information, please contact:

 
Instem plc                        +44 (0) 1785 825 600 
Phil Reason, CEO 
Nigel Goldsmith, CFO 
 
N+1 Singer (Nominated Adviser & 
 Broker)                          +44 (0) 20 7496 3000 
Aubrey Powell 
Joe Stroud 
 
Newgate Threadneedle              +44 (0) 20 7653 9850 
Caroline Evans-Jones 
Fiona Conroy 
 

About Instem plc

Instem is a leading supplier of IT solutions to the early development healthcare market. Instem's pre-clinical study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.

Instem has over 130 customers in North America, Europe, China, India and Japan, including 16 of the top 20 pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Group employs over 110 people in seven offices in the US, UK, China and India; and has a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software, making Instem an ideal partner to help unlock the scientific/commercial value from these legacy repositories.

To learn more about Instem please visit the Company's website, www.instem.com, or its investor centre http://investors.instem.com/

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBRGDBRSBBGXS

Instem (LSE:INS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Instem Charts.
Instem (LSE:INS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Instem Charts.